Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Claritas Pharmaceuticals Inc (CLAS.VN)

Claritas Pharmaceuticals Inc (CLAS.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 915
  • Shares Outstanding, K 36,586
  • Annual Sales, $ 0 K
  • Annual Income, $ 4,210 K
  • 60-Month Beta 2.53
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.20
Trade CLAS.VN with:
  • Price/Earnings ttm 0.20
  • Earnings Per Share ttm -0.13
  • Most Recent Earnings $0.01 on N/A
  • Latest Earnings Date 01/02/23
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.025 unch
on 07/19/22
0.055 -54.55%
on 06/20/22
-0.025 (-50.00%)
since 06/17/22
3-Month
0.025 unch
on 07/19/22
0.145 -82.76%
on 04/25/22
-0.115 (-82.14%)
since 04/19/22
52-Week
0.025 unch
on 07/19/22
0.750 -96.67%
on 07/23/21
-0.375 (-93.75%)
since 07/19/21

Most Recent Stories

More News
Claritas Announces Approval from OTC to Up-List to OTCQB

SAN FRANCISCO, CA and TORONTO, ON, April 07, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: CLAZF) (the...

CLAS.VN : 0.025 (-16.67%)
OTC.VN : 0.325 (+3.17%)
CLAS : 10.17 (+0.20%)
CLAZF : 0.0001 (unch)
Claritas Announces Approval from Australian Ethics Committee to Begin Phase 1 Trial of R-107

SAN FRANCISCO, CA and TORONTO, ON, April 05, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: CLAZF) (the...

CLAS.VN : 0.025 (-16.67%)
OTC.VN : 0.325 (+3.17%)
CLAS : 10.17 (+0.20%)
CLAZF : 0.0001 (unch)
Claritas Announces Receipt of Comments from Australian Ethics Committee Regarding the Company’s Phase 1 Clinical Study of R-107 and Closing of Financing

SAN FRANCISCO, CA and TORONTO, ON , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or...

OTC.VN : 0.325 (+3.17%)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)
Claritas Anticipates Response from Australian Ethics Committee by February 18, 2022

Ethics Committee Approval is Final Step Prior to Enrollment of Claritas’ Phase 1 Clinical Study of R-107...

OTC.VN : 0.325 (+3.17%)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)
Claritas Announces Revised, Improved Terms for Initial Tranche of Financing with Alumina Partners

SAN FRANCISCO, CA and TORONTO, ON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or...

OTC.VN : 0.325 (+3.17%)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)
Claritas Announces Letter of Intent to Acquire Worldwide Rights to R-107 for Treatment of Wound Healing, Skin Ulcers and Severe Burns

SAN FRANCISCO, CA and TORONTO, ON, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or...

CLAS.VN : 0.025 (-16.67%)
OTC.VN : 0.325 (+3.17%)
KLY.VN : 0.045 (unch)
KALTF : 0.1100 (unch)
Claritas Announces New Registered and Records Office Address, Confirms its Management and Directors and Announces Terms of Initial Tranche of Equity Financing with Alumina Partners

SAN FRANCISCO, CA and TORONTO, ON, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or...

OTC.VN : 0.325 (+3.17%)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)
Claritas Secures $5 Million Equity Financing Facility with Alumina Partners (Ontario) Ltd.

SAN FRANCISCO, CA and TORONTO, ON, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or...

OTC.VN : 0.325 (+3.17%)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)
Claritas to Develop R-107 for Treatment of PPHN, a Potentially Fatal Pulmonary Disorder in Newborns

SAN FRANCISCO, CA, and TORONTO, ON, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or...

OTC.VN : 0.325 (+3.17%)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)
Claritas Completes Acquisition of Exclusive Worldwide Rights to Develop and Commercialize R-107 for Pulmonary Disease

Data in Animal Model of PAH Demonstrate Ability of R-107 to Reverse Progression of the Disease...

OTC.VN : 0.325 (+3.17%)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Claritas Pharmaceuticals Inc is a clinical-stage specialty pharmaceutical company developing a portfolio of pharmaceutical products in Canada. It develops new treatments for a variety of diseases and disorders, by discovering, developing, manufacturing, and delivering human therapeutics.

See More

Key Turning Points

3rd Resistance Point 0.025
2nd Resistance Point 0.025
1st Resistance Point 0.025
Last Price 0.025
1st Support Level 0.025
2nd Support Level 0.025
3rd Support Level 0.025

See More

52-Week High 0.750
Fibonacci 61.8% 0.473
Fibonacci 50% 0.387
Fibonacci 38.2% 0.302
Last Price 0.025
52-Week Low 0.025

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar